Search PubMed⌕ Search

Biomedical subjects

K K Jindal

Publications and source records attributed to K K Jindal.

At least 37 records · Page 2Linked to original sources
PubMed1994

Excellent technique survival on home peritoneal dialysis: results of a regional program.

OBJECTIVE: To examine peritoneal dialysis technique survival in our regional, continuous ambulatory peritoneal dialysis (CAPD) program. DESIGN: Retrospective analysis. SETTING: Tertiary care dialysis program at an academic medical center. PATIENTS: 155 patients representing all those in the peritoneal dialysis program between October 1, 1987 and October 1, 1990. OUTCOME MEASURES: The study analyzed patient and technique survival as well as the reasons for discontinuation of dialysis. In addition, the incidence and type of peritonitis and exit-site infection were also analyzed. RESULTS: Three-year actuarial patient survival was 66% and three-year technique survival was 86%, with data censored for death and transplant patients. Fifty-seven percent of transfers to hemodialysis were due to peritonitis, usually fungal or multiorganism bacterial. Only 1 patient failed due to exit-site and tunnel infection, and 1 due to inadequate dialysis. The catheter removal rate was 0.04 per patient-year. CONCLUSIONS: Excellent CAPD technique survival can be achieved if exit-site and tunnel infection rates are low.

Female↗
PubMed1992

Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure.

Although erythropoietin (Epo) is known to correct anaemia in dialysis and pre-dialysis patients, there is limited experience with its use in immunosuppressed patients suffering from chronic renal graft dysfunction. We report the results of a pilot study of Epo in seven patients with failing grafts and normocytic normochromic anaemia attributable to renal failure. All entering patients had controlled blood pressure and serum ferritin greater than 100 micrograms/l. Three patients were taking triple immunotherapy (prednisone/azathioprine/cyclosporin), two patients prednisone/azathioprine, and two patients CsA monotherapy. Study duration mean was 15 +/- 2 (SEM) weeks, and Epo was started at 4000 units subcutaneously (s.c.) once weekly, adjusted to achieve a target haemoglobin (Hb) of 100 g/l. Mean Hb at initiation was 68 +/- 5 g/l and significantly increased to 96 +/- 6 at end of follow-up, P less than 10(-4). All patients responded. Maintenance Epo dosage was 120 +/- 32 U/kg bodyweight/week, roughly 4000 units/week. There was no significant change in serum creatinine: pre-study 392 +/- 45 mumol/l; post-study 430 +/- 62 mumol/l. There were no complications but blood pressure did rise significantly: pre- 124 +/- 11/74 +/- 4 mmHg to post- 142 +/- 10/86 +/- 3, P less than 0.05 for systolic and diastolic. Low-dose s.c. Epo effectively corrects anaemia in graft failure despite azathioprine and/or CsA therapy, without obvious acceleration of graft failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1991

Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine.

Subclavian catheter (SCC) related infections are a major cause of morbidity in hemodialysis patients, the vast majority due to staphylococci species. Povidone-iodine (PI) has proven anti-staphylococcal activity. Therefore, a randomized controlled trial of topical PI ointment was undertaken to evaluate the impact of this prophylactic intervention on the incidence of SCC related infections in hemodialysis patients. The role of S. aureus nasal carrier state in the acquisition of infection was also evaluated. Patients requiring SCC for temporary hemodialysis access were randomized to receive the treatment (T; N = 63) or sterile gauze dressings alone (C; N = 66). Catheter duration ranged from 2 to 210 days in both groups, with a mean of 38.6 days in T and 36.2 days in C (NS). Exit site (ES) infections were significantly less in T (5%) versus C (18%) (P less than 0.02); tip colonization (TC) was 17% in T versus 36% in C (P less than 0.01), while the incidence of septicemia (S) was also significantly less in T (2%) versus C (17%; P less than 0.01). S. aureus nasal carriers were at a threefold higher risk of SCC related septicemia (0.009/day) than noncarriers (0.003/day; P less than 0.05). The beneficial effect of PI ointment was most evident in this high risk group of S. aureus carriers: ES = 0% T versus 24% C, TC = 12% T versus 42% C, S = 0% T versus 29% C, P less than 0.05. There were no adverse effects of the treatment. The routine application of topical PI ointment to temporary hemodialysis catheter exit sites is effective in reducing SCC related infections.

Acute Kidney Injury↗
PubMed1991

Late leaks in peritoneal dialysis patients.

A series of eight patients with leakage of dialysate around the exit site of their peritoneal dialysis catheters is reviewed. In all cases the leak occurred at least 1 month after catheter placement. There were no risk factors allowing prediction of leakage. Four cases required surgical intervention, and all patients returned to CAPD.

Adult↗
PubMed1991

Crescentic IgA nephropathy as a manifestation of human immune deficiency virus infection.

A 37-year-old Caucasian male homosexual presented with hematuria and rapidly progressive acute renal failure. He was found to have proteinuria and microscopic hematuria as well as RBC casts. Investigations revealed polyclonal gammopathy with five times normal serum IgA levels as well as elevated serum IgG. Renal biopsy showed evidence of crescentic IgA nephropathy with ultrastructural changes of tubuloreticular inclusions described in HIV nephropathy. He was found to be positive for human immunodeficiency viral antibodies. Renal function improved during follow-up after two doses of 1 g each of methylprednisone. In our opinion, this is the first case of HIV-related crescentic IgA nephropathy. HIV testing should be performed more frequently in patients presenting with acute glomerular diseases.

AIDS-Associated Nephropathy↗
PubMed1989

A study of the basic principles determining the performance of several high-flux dialyzers.

The clearance characteristics of several commercially available high-flux dialyzers made from cellulose acetate, polyacrylonitrile, polysulphone, and polymethylmethacrylate were studied in vivo. The impact of increasing surface area and adding ultrafiltration on the clearances of small- and larger-molecular-weight species was assessed. The results show there are major differences in large-molecular-weight substance substance handling by different dialyzers as shown by differences in beta 2-microglobulin clearance, independent of ultrafiltration capacity. Membranes made from similar material, eg, Asahi's PAN and Hospal's AN-69 membrane, both made from polyacrylonitrile, differ significantly in their beta 2-microglobulin clearance. Increased surface area results in much greater increase in large-molecular-weight substance clearance. The present study clearly demonstrates that high water flux is not related to high large-molecular-weight permeability. Decisions with respect to impact on dialysis must be based on a knowledge of both the large- and small-molecular-weight permeabilities of the various membranes.

Acrylic Resins↗
PubMed1987

A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis.

Patients with membranous glomerulonephritis (MGN), impaired renal function and the nephrotic syndrome are at high risk of developing renal failure. Twenty-six such patients were studied with serum creatinine concentrations exceeding 135 microM, and 24-hour urine protein excretion of at least 3.5 g/day to determine the potential benefit of cyclophosphamide therapy. Cyclophosphamide (mean 1.5 mg/kg/day) was given to nine patients for 23 +/- 4 months. These patients were compared with 17 concurrent controls. The two groups did not differ in clinical or laboratory features at the time of biopsy or start of treatment or its equivalent. Six of the nine cyclophosphamide treated patients and 15 of the 17 controls had received prednisone therapy. The total follow-up was 49 +/- 10 months in the treated group and 50 +/- 6 months in the controls. At last observation, serum creatinine values exceeded 400 microM in eight controls (4 on dialysis) and in none of the treated patients. The mean serum creatinine level was significantly lower (P less than 0.02) in the treated group (173 +/- 24 microM) than in controls (433 +/- 71 0.02) in the treated group (173 +/- 24 microM) than in controls (433 +/- 71 microM). The mean serum albumin level and 24-hour urine protein excretion both improved significantly with treatment as compared with controls. There were four complete remissions, five partial remissions and no patient with persistent nephrotic syndrome after treatment. In the controls, there were no complete remissions, six partial remissions and 11 patients had persistent nephrotic syndrome (P less than 0.001). Thus, cyclophosphamide therapy appears to be of benefit in patients with MGN, the nephrotic syndrome and impaired renal function.

Adult↗
PubMedDate not supplied

Progressive increases in peritoneal dialysis prescription: patient acceptance and complication rates.

Peritoneal dialysis adequacy has an impact on patient mortality. Both the CANUSA study and DOQI Guidelines outline targets for adequacy, and it has been suggested that quantitative adequacy determinations be made at regular intervals. Some groups believe these targets are not achievable because of lack of patient acceptance and high complication rate. We examined the outcome of peritoneal dialysis in a setting where prescription changes are made on clinical grounds, and determined the complication rates and patient acceptance of prescription changes. A total of 154 patients commencing peritoneal dialysis from January 1, 1994,-December 31, 1996, were studied to determine reasons for dialysis prescription changes, patient acceptance of, and complications related to these changes. Point prevalence data for dialysis prescription for our center and other Canadian centers were obtained from the Canadian Institute for Health Information. Co-morbidity - adjusted patient and technique survival for our center versus other centers in Canada was performed by Poisson regression analysis. Dialysis prescription changes were based on clinical assessment. A total of 102 patients started on either > 8 L of dialysate or had an increase in dialysis prescription during the study period. These patients were heavier, on peritoneal dialysis for longer, and fewer were transplanted compared with the patients on standard prescription (8 L or less). Only 4% of patients refused the change in dialysis prescription, and only 13 peritoneal leaks occurred, resulting in 3 transfers to hemodialysis. Our center prescribed a larger number of exchanges than other Canadian centers in 1995-1997. Adjusted mortality rate ratios for our center versus the other Canadian Centers (1990-1996) are equal. The 3 year technique survival for peritoneal dialysis patients from our center between 1990-1996 was 75% vs. 61% for other centers in Canada. At last follow-up, > 60% of patients had a Kt/V urea >2.1 and 45% had a creatinine clearance > 70 L/1.73 m2/week. This Regional Program has successfully prescribed high volume and frequency peritoneal dialysis on clinical grounds alone. This practice is associated with high patient acceptance, equivalent mortality, and higher technique survival compared with the rest of Canada.

Aged↗